About Autobahn Therapeutics
Autobahn Therapeutics is a company based in San Diego (United States) founded in 2019. Autobahn Therapeutics has raised $227.53 million across 4 funding rounds from investors including Pfizer, ARE and Biogen. Autobahn Therapeutics offers products and services including ABX-002, ABX-101, and ABX-003. Autobahn Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Harmony Biosciences, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$227.53 M (USD)
in 4 rounds
-
Latest Funding Round
$100.83 M (USD), Series C
Jun 20, 2024
-
Investors
Pfizer
& 16 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Autobahn Therapeutics
Autobahn Therapeutics offers a comprehensive portfolio of products and services, including ABX-002, ABX-101, and ABX-003.
Therapy for adjunctive treatment of bipolar depression.
Next-generation S1P modulator for CNS disorders.
Regenerative medicine targeting brain disorders.
People of Autobahn Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Autobahn Therapeutics
Autobahn Therapeutics has successfully raised a total of $227.53M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $100.83 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Autobahn Therapeutics
Autobahn Therapeutics has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, ARE and Biogen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment management services are offered by Newpath Partners.
|
Locked | Locked | Locked | |
|
Canaan is recognized as an early-stage venture capital firm.
|
Locked | Locked | Locked | |
|
Monograph Capital is focused on life sciences investment.
|
Locked | Locked | Locked |
Investor details for Autobahn Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Autobahn Therapeutics
Investment portfolio details for Autobahn Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Autobahn Therapeutics
Detailed financials for Autobahn Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Autobahn Therapeutics Comparisons
Peer comparison for Autobahn Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Autobahn Therapeutics
Autobahn Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Harmony Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for rare neurological diseases
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Autobahn Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Autobahn Therapeutics
Complete news archive for Autobahn Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Autobahn Therapeutics
Autobahn Therapeutics was founded in 2019.
Autobahn Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Kevin Finney is the current CEO of Autobahn Therapeutics.
Autobahn Therapeutics is a funded company, having raised a total of $227.53M across 4 funding rounds to date.
Autobahn Therapeutics was founded in 2019 and is based in San Diego, United States. Regenerative medicine is utilized to develop therapeutics targeting central nervous system disorders. The pipeline features ABX-002, which addresses thyroid hormone and myelin biology for multiple sclerosis and adrenomyeloneuropathy treatments. A platform is employed to create orally administered prodrugs that modulate brain chemistry for CNS disease applications.
Autobahn Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Autobahn Therapeutics offers ABX-002, ABX-101, and ABX-003.
Autobahn Therapeutics has 17 investors. Key investors include Pfizer, ARE, Biogen, TD Securities, and Arch Venture Partners.